Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET
Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced plans to present topline clinical data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 during an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET.
The Company also plans to present the full clinical dataset and additional analyses from the OPGx-BEST1 program at several upcoming medical conferences.
Investor Conference Call and Webcast
Opus Genetics will host an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET to present topline data from Cohort 1 of the Phase 1/2 clinical study of OPGx-BEST1.
Date: Wednesday, September 9, 2026
Time: 8:00 a.m. ET
Webcast: Opus Genetics Investor Events
A live webcast and accompanying presentation will be available in the Investors section of the Company’s website. A replay will be available following the event.
Upcoming Conference Presentations
Euretina Innovation Spotlight (EIS)
Date: Wednesday, September 30, 2026
Time: 14:20-14:56 CEST
Presenter: Ben Yerxa
Title: Advancing the Future of IRDs: Opus Genetics Clinical Development Update
Euretina 2026
Date: Sunday, October 4, 2026
Time: 13:15-13:21 CEST
Presenter: Mark Pennesi, M.D., Ph.D., Professor of Ophthalmology, School of Medicine, Casey Eye Institute, School of Medicine
Title: Initial Results from Cohort 1 of a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations
Retina in Rio
Date: Wednesday, October 14, 2026
Title: Structure-Function Correlation of EZ-RPE Thickness and MAIA Microperimetry in BEST1-Related Retinopathy: Results from the Phase 1/2 BIRD-1 Study of OPGx-BEST1 Gene Therapy
Presenter: George Magrath, M.D, CEO, Opus Genetics
Title: Near Normalization of Cone Sensitivity using Gene Augmentation in Children with LCA5
Presenter: Rodrigo Jorge, M.D., Ph.D., Head of Ophthalmology Department at University of São Paulo
FLORetina Presentation
Title: Phase 1/2 Cohort 1 3M Results of OPGx-BEST1 Gene Therapy in Patients with BVMD and ARB Due to BEST1 Mutations
Presenter: Aaron Nagiel, M.D., Ph.D.
About OPGx-BEST1
OPGx-BEST1 is an investigational gene therapy designed to address the underlying genetic cause of BEST1-related inherited retinal diseases, including BVMD and ARB. OPGx-BEST1 uses an AAV vector to deliver a functional copy of the BEST1 gene to retinal pigment epithelial cells. The ongoing BIRD-1 study is an adaptive, open-label Phase 1/2 clinical trial evaluating the safety and efficacy of single-eye subretinal administration of OPGx-BEST1 in adults with BVMD or ARB.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Contacts
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
[email protected]
Media
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]